Table I.
Patient (n=40) and tumor characteristics at recurrence.
| Characteristics | n (%) |
|---|---|
| Sex | |
| Male | 27 (68) |
| Female | 13 (32) |
| Median age, years (range) | 54 (25–75) |
| Karnofsky performance status | |
| Median (range) | 80 (60–90) |
| 90–100 | 7 (17) |
| 70–80 | 28 (70) |
| 60 | 5 (13) |
| Laterality | |
| Right | 22 (55) |
| Left | 18 (45) |
| Histotype | |
| Glioblastoma multiforme | 34 (85) |
| Anaplastic glioma | 6 (15) |
| MGMT promoter methylation status at diagnosis | |
| Methylated | 20 (50) |
| Unmethylated | 16 (40) |
| Unknown | 4 (10) |
| IDH mutation status at diagnosis | |
| Mutated | 11 (28) |
| Non mutated | 16 (40) |
| Unknown | 13 (32) |
| Surgery at recurrence | |
| Yes | 25 (63) |
| No | 15 (37) |
| RT at recurrence | |
| Yes | 17 (42) |
| No | 23 (58) |
| Interval between completion of RT/TMZ and recurrence | |
| ≤3 months | 7 (17) |
| >3 months | 33 (83) |
| No. of lines of chemotherapy after FTM | |
| None | 24 (60) |
| One | 11 (28) |
| Two | 3 (7) |
| In progress with FTM | 2 (5) |
| Median cycles received, no. (range) | 5 (2–50) |
| Induction phase completed | |
| Yes | 27 (68) |
| No | 13 (32) |
MGMT O6-methylguanine-DNA-methyltransferase; IDH, isocitrate dehydrogenase; RT, radiotherapy; TMZ, temozolomide, FTM, fotemustine.